肠道微生物与心血管疾病的相关性研究进展

Research Progress in Correlation between Gut Microbiome and Cardiovascular Disease

心血管疾病(CVD)已成为威胁人类生命的主要疾病,遗传和环境因素共同参与其发病过程。肠道作为人体最大的微生态系统,聚集着大量细菌、真菌、病毒、原生动物等,肠道微生物在人类的健康和疾病中起重要作用,其产生的代谢产物可以影响宿主的生理作用,与CVD的发生发展密切相关。肠道微生物的主要代谢产物三甲胺-N-氧化物(TMAO)和短链脂肪酸参与CVD的发病机制,并与不良心血管事件的发生风险呈正相关。未来,肠道微生物将成为CVD治疗的一个潜在靶点,靶向抑制产生TMAO的菌群可能是一种新型的治疗策略。

Cardiovascular disease(CVD)has become a major disease threatening human life.Genetic and environmental factors are involved in the pathogenesis of CVD.As the largest microecosystem of human body,intestinal tract is home to a large number of bacteria,fungi,viruses,protozoa,etc.Gut microbiome plays an important role in human health and disease,the metabolites generated from which can affect the physiological role of the human host and are closely related to the occurrence and development of CVD.Trimethylamine-N-oxide(TMAO)and short-chain fatty acids,the main metabolites of gut microbiome,play a vital role in the pathogenesis of CVD and are positively correlated with the risk of adverse cardiovascular events.Gut microbiome regulation will become a potential therapeutic target for CVD,and inhibition of flora producing TMAO might be a novel therapeutic strategy in the future.